Arcturus Therapeutics' COVID-19 Booster Clinical Trial Show Encouraging Neutralizing Antibody Responses


Arcturus Therapeutics Holdings Inc ARCT has announced updated data Phase 1/2 booster trial of ARCT-154 and ARCT-165, its investigational, self-amplifying mRNA COVID-19 vaccine candidates targeting the variants of concern.

  • Data from the Phase 1/2 booster trial show that both ARCT-154 and ARCT-165, when administered as low-dose (5 mcg) boosters at least five months after Pfizer Inc's PFE - BioNTech SE's BNTX Comirnaty immunization, demonstrated robust antibody responses.
  • Related: Arcturus Shares Shoot Higher After Additional Data From COVID-19 Vaccine Programs.
  • Neutralizing antibody concentrations were maintained between 15 and 29 days post-administration. 
  • These results are expected to support further clinical development of these candidates as booster vaccines.
  • Price Action: ARCT shares are down 6.47% at $23.00 during the premarket session on Monday's last check.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareSmall CapMoversTrading IdeasGeneralBriefsCOVID-19 CoronavirusCOVID-19 Vaccine
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!